MedPath

Neurelis, Inc.

Neurelis, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2007-01-01
Employees
101
Market Cap
-
Website
http://www.neurelis.com

Clinical Trials

4

Active:0
Completed:4

Trial Phases

2 Phases

Phase 1:3
Phase 3:1

Drug Approvals

4

NMPA:3
FDA:1

Drug Approvals

Diazepam Nasal Spray

Product Name
地西泮鼻喷雾剂
Approval Number
国药准字HJ20230065
Approval Date
Jun 7, 2023
NMPA

Diazepam Nasal Spray

Product Name
地西泮鼻喷雾剂
Approval Number
国药准字HJ20230067
Approval Date
Jun 7, 2023
NMPA

Diazepam Nasal Spray

Product Name
地西泮鼻喷雾剂
Approval Number
国药准字HJ20230066
Approval Date
Jun 7, 2023
NMPA

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (75.0%)
Phase 3
1 (25.0%)

A Study of Olanzapine After Intranasal and Intramuscular Administration

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
Neurelis, Inc.
Target Recruit Count
24
Registration Number
NCT06600477
Locations
🇯🇴

International Pharmaceutical Research Center (IPRC) Clinical Site, Amman, Jordan

Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy

Phase 1
Completed
Conditions
Epilepsy
Interventions
First Posted Date
2021-10-13
Last Posted Date
2025-08-11
Lead Sponsor
Neurelis, Inc.
Target Recruit Count
35
Registration Number
NCT05076838
Locations
🇺🇸

Northwest Florida Clinical Research Group, LLC., Gulf Breeze, Florida, United States

🇺🇸

Nicklaus Children's Hospital, Miami, Florida, United States

🇺🇸

AdventHealth Research Institute, Orlando, Florida, United States

and more 10 locations

Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects

Phase 1
Completed
Conditions
Acute Repetitive Seizures
Interventions
First Posted Date
2016-03-31
Last Posted Date
2021-10-05
Lead Sponsor
Neurelis, Inc.
Target Recruit Count
57
Registration Number
NCT02724423
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

🇺🇸

Le Bonheur Children's Hospita, Memphis, Tennessee, United States

and more 1 locations

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

Phase 3
Completed
Conditions
Acute Repetitive Seizures
Breakthrough Seizures
Interventions
First Posted Date
2016-03-28
Last Posted Date
2022-01-31
Lead Sponsor
Neurelis, Inc.
Target Recruit Count
175
Registration Number
NCT02721069
Locations
🇺🇸

Clinical Trials, Inc., Little Rock, Arkansas, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.